Earnings ·
BioAge Labs reports Q3 net loss of $33.5M as BGE-102 trials advance
BIOABioAge Labs, Inc.
BioAge Labs reported a third-quarter net loss of $33.5 million, or $0.73 per share, compared to a $20.2 million loss in the prior-year period. The widening deficit was driven by an $11.7 million increase in research and development expenses, primarily due to clinical trial costs for the BGE-102 program's QUELL-CV and QUELL-DME trials. Collaboration revenue fell to $0.3 million from $2.1 million following a Novartis agreement amendment. The company holds approximately $352.3 million in cash and expects funding through 2029. BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging.